June 12, 2018 Newport Coast CA – VivoSense (Vivonoetics), the leading provider of visualization and analysis software for data from wearable sensors is excited to announce the release of VivoSense® 3.2.
With the accelerating adoption of wearable physiological sensors, large complex clinical trial data sets are being generated across a wide variety patient populations and disease states, including rare diseases. VivoSense® 3.2 provides the most rigorous analyses of these data possible in providing the endpoints and biomarkers which withstand Regulatory scrutiny and academic oversight.
If you have VivoSense® 3.0 or greater, please install the latest version, or request a free trial license.
As a company VivoSense is committed to providing robust clinical endpoints for industry leading biotechnology, pharma, CROs and healthcare providers including Roche, Mayo Clinic, Nationwide Children’s Hospital and Harvard University.
